Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel

Yu-Sheng Wu, Janet Jiang, Saumel Ahmadi, Alexandria Lew, Onofrio Laselva, Sunny Xia, Claire Bartlett, Wan Ip, Leigh Wellhauser, Hong Ouyang, Tanja Gonska, Theo J. Moraes and Christine E. Bear
Molecular Pharmacology October 2019, 96 (4) 515-525; DOI: https://doi.org/10.1124/mol.119.117143
Yu-Sheng Wu
Programmes in Translational Medicine (Y.-S.W., C.B., W.I., H.O., T.G., T.J.M.) and Molecular Medicine (Y.-S.W., J.J., S.A., A.L., O.L., S.X., L.W., C.E.B.), Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada; and Departments of Laboratory Medicine and Pathobiology (T.J.M.), Biochemistry (C.E.B.), Physiology (Y.-S.W., S.A., O.L., S.X., C.E.B.), and Paediatrics (T.G., T.J.M.), University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janet Jiang
Programmes in Translational Medicine (Y.-S.W., C.B., W.I., H.O., T.G., T.J.M.) and Molecular Medicine (Y.-S.W., J.J., S.A., A.L., O.L., S.X., L.W., C.E.B.), Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada; and Departments of Laboratory Medicine and Pathobiology (T.J.M.), Biochemistry (C.E.B.), Physiology (Y.-S.W., S.A., O.L., S.X., C.E.B.), and Paediatrics (T.G., T.J.M.), University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saumel Ahmadi
Programmes in Translational Medicine (Y.-S.W., C.B., W.I., H.O., T.G., T.J.M.) and Molecular Medicine (Y.-S.W., J.J., S.A., A.L., O.L., S.X., L.W., C.E.B.), Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada; and Departments of Laboratory Medicine and Pathobiology (T.J.M.), Biochemistry (C.E.B.), Physiology (Y.-S.W., S.A., O.L., S.X., C.E.B.), and Paediatrics (T.G., T.J.M.), University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandria Lew
Programmes in Translational Medicine (Y.-S.W., C.B., W.I., H.O., T.G., T.J.M.) and Molecular Medicine (Y.-S.W., J.J., S.A., A.L., O.L., S.X., L.W., C.E.B.), Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada; and Departments of Laboratory Medicine and Pathobiology (T.J.M.), Biochemistry (C.E.B.), Physiology (Y.-S.W., S.A., O.L., S.X., C.E.B.), and Paediatrics (T.G., T.J.M.), University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Onofrio Laselva
Programmes in Translational Medicine (Y.-S.W., C.B., W.I., H.O., T.G., T.J.M.) and Molecular Medicine (Y.-S.W., J.J., S.A., A.L., O.L., S.X., L.W., C.E.B.), Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada; and Departments of Laboratory Medicine and Pathobiology (T.J.M.), Biochemistry (C.E.B.), Physiology (Y.-S.W., S.A., O.L., S.X., C.E.B.), and Paediatrics (T.G., T.J.M.), University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sunny Xia
Programmes in Translational Medicine (Y.-S.W., C.B., W.I., H.O., T.G., T.J.M.) and Molecular Medicine (Y.-S.W., J.J., S.A., A.L., O.L., S.X., L.W., C.E.B.), Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada; and Departments of Laboratory Medicine and Pathobiology (T.J.M.), Biochemistry (C.E.B.), Physiology (Y.-S.W., S.A., O.L., S.X., C.E.B.), and Paediatrics (T.G., T.J.M.), University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Bartlett
Programmes in Translational Medicine (Y.-S.W., C.B., W.I., H.O., T.G., T.J.M.) and Molecular Medicine (Y.-S.W., J.J., S.A., A.L., O.L., S.X., L.W., C.E.B.), Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada; and Departments of Laboratory Medicine and Pathobiology (T.J.M.), Biochemistry (C.E.B.), Physiology (Y.-S.W., S.A., O.L., S.X., C.E.B.), and Paediatrics (T.G., T.J.M.), University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wan Ip
Programmes in Translational Medicine (Y.-S.W., C.B., W.I., H.O., T.G., T.J.M.) and Molecular Medicine (Y.-S.W., J.J., S.A., A.L., O.L., S.X., L.W., C.E.B.), Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada; and Departments of Laboratory Medicine and Pathobiology (T.J.M.), Biochemistry (C.E.B.), Physiology (Y.-S.W., S.A., O.L., S.X., C.E.B.), and Paediatrics (T.G., T.J.M.), University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leigh Wellhauser
Programmes in Translational Medicine (Y.-S.W., C.B., W.I., H.O., T.G., T.J.M.) and Molecular Medicine (Y.-S.W., J.J., S.A., A.L., O.L., S.X., L.W., C.E.B.), Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada; and Departments of Laboratory Medicine and Pathobiology (T.J.M.), Biochemistry (C.E.B.), Physiology (Y.-S.W., S.A., O.L., S.X., C.E.B.), and Paediatrics (T.G., T.J.M.), University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Ouyang
Programmes in Translational Medicine (Y.-S.W., C.B., W.I., H.O., T.G., T.J.M.) and Molecular Medicine (Y.-S.W., J.J., S.A., A.L., O.L., S.X., L.W., C.E.B.), Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada; and Departments of Laboratory Medicine and Pathobiology (T.J.M.), Biochemistry (C.E.B.), Physiology (Y.-S.W., S.A., O.L., S.X., C.E.B.), and Paediatrics (T.G., T.J.M.), University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanja Gonska
Programmes in Translational Medicine (Y.-S.W., C.B., W.I., H.O., T.G., T.J.M.) and Molecular Medicine (Y.-S.W., J.J., S.A., A.L., O.L., S.X., L.W., C.E.B.), Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada; and Departments of Laboratory Medicine and Pathobiology (T.J.M.), Biochemistry (C.E.B.), Physiology (Y.-S.W., S.A., O.L., S.X., C.E.B.), and Paediatrics (T.G., T.J.M.), University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theo J. Moraes
Programmes in Translational Medicine (Y.-S.W., C.B., W.I., H.O., T.G., T.J.M.) and Molecular Medicine (Y.-S.W., J.J., S.A., A.L., O.L., S.X., L.W., C.E.B.), Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada; and Departments of Laboratory Medicine and Pathobiology (T.J.M.), Biochemistry (C.E.B.), Physiology (Y.-S.W., S.A., O.L., S.X., C.E.B.), and Paediatrics (T.G., T.J.M.), University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine E. Bear
Programmes in Translational Medicine (Y.-S.W., C.B., W.I., H.O., T.G., T.J.M.) and Molecular Medicine (Y.-S.W., J.J., S.A., A.L., O.L., S.X., L.W., C.E.B.), Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada; and Departments of Laboratory Medicine and Pathobiology (T.J.M.), Biochemistry (C.E.B.), Physiology (Y.-S.W., S.A., O.L., S.X., C.E.B.), and Paediatrics (T.G., T.J.M.), University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    CF-associated defect in arginine-dependent NO production in bronchial epithelia is partially rescued by the arginase inhibitor, CB-1158. Epithelial NO levels were measured using DAF-FM fluorophore in WT- and F508del-CFTR primary bronchial cells following simultaneous 1-hour pretreatment with 1 mM L-arginine ± 10 µM CB-1158 and the appropriate buffer control. Calculations were generated by normalizing the NO concentration to cell density (the ratio of DAF-FM to the live cell marker, Calcein Blue AM) to compare between the two patient genotypes. Bars represent mean ± S.D. One-way ANOVA with Tukey’s multiple comparison test was performed. (ns = not statistically significant; **P < 0.01; ***P < 0.002; ****P < 0.0001, N > 4 biologic replicates, n = 2 to 3 technical replicates).

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Pretreatment with arginase inhibitor CB-1158 increases NO pathway–driven CFTR channel activity in CFBE cells transduced with lv (lentivirus). SLC6A14. (A) Traces normalized to 5 minutes (timepoint at the end of baseline) represent change in FLIPR fluorescence from baseline (depolarization due to ACC: ΔF/F0) relative to buffer control, as a measure of CFTR channel function in CFBE stably expressing F508del-CFTR with lv. SLC6A14. Cells were pretreated 1 hour with 10 µM CB-1158, 50 µM 1400 W, combination of CB-1158 and 1400 W, or buffer in the FLIPR dye solution. At the 5-minute point, 1 mM L-arginine was added into the apical bath, and, at 15 minutes, cAMP stimulation occurred due to 10 µM FSK addition. At 25 minutes, CFTR-specific inhibitor, CFTRinh-172 (Inh-172), was added to confirm CFTR-specific function. (B) Bar graph represents maximum change in ACC fluorescence after Fsk addition to the peak of Fsk response (ΔFsk/F0) following 1 mM L-arginine in the CFBE cell line from (A) (mean ± S.D.). One-way ANOVA with Tukey’s multiple comparison test was performed (ns = not statistically significant, *P < 0.05; **P < 0.01, N = 3 biologic replicates, n = 4 technical replicates).

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Inhibition of arginase activity enhances rescue of F508del-CFTR channel activity at the surface of primary respiratory epithelial tissues by VX-809 plus VX-770. (A) Bar graph represents maximum change in ACC fluorescence from baseline (ΔF/F0) normalized to mock activation (with DMSO as vehicle control for arginine or FSK plus VX-770) for F508del-CFTR primary bronchial cells with 48-hour chronic treatment with either DMSO or 3 µM VX-809 (meanEmbedded Image S.D.). Cells were pretreated acutely for 1 hour with 1 mM L-arginine, 10 µM CB-1158, 10 µM ABH, or buffer in the FLIPR dye solution. WT baseline is based on the mean FSK-stimulated values of eight individual WT-CFTR primary bronchial cells. One-way ANOVA with Tukey’s multiple comparison test relative to VX-809 plus VX-770 was performed (**P < 0.007; ****P < 0.0001, N > 4 biologic replicates, n = 2 technical replicates). (B) Representative line graphs represent change in ACC fluorescence from baseline (ΔF/F0) relative to DMSO control, as a measure of CFTR channel function in F508del-CFTR bronchial cells grown on inserts at ALI with 48-hour chronic treatment of 3 µM VX-809 or DMSO. Cells were pretreated with 10 µM CB-1158, or buffer in the FLIPR dye solution. At the 10-minute point, 1 mM L-arginine (Arg) was added into the apical FLIPR membrane dye solution, and, at 25 minutes, cAMP stimulation (Stim) occurred due to 10 µM FSK and 1 µM VX-770 addition. At 45 minutes, CFTR-specific inhibitor, CFTRinh-172 (Inh172), was added as an indicator of CFTR-specific function. (C) Bar graph represents the maximum change in ACC fluorescence from baseline (ΔF/F0) normalized to first DMSO control on F508del-CFTR primary nasal cells with 48-hour chronic treatment of either DMSO or 3 µM VX-809 (meanEmbedded Image S.D.). Cells are pretreated for 1 hour with 10 µM CB-1158, or buffer in the FLIPR dye solution. WT baseline is based on the mean FSK-stimulated values of 16 individual WT-CFTR primary nasal cells. One-way ANOVA with Tukey’s multiple comparison test was performed (ns = not statistically significant, *P < 0.04; ***P = 0.005, N = 3 biologic replicates, n = 1 to 2 technical replicates). (D) Representative trace shows change in ACC fluorescence from baseline (ΔF/F0) relative to DMSO control, as a measure of CFTR channel function in F508del-CFTR nasal cells grown on inserts at ALI for 14 days with 48-hour chronic treatment of 3 µM VX-809 or DMSO. Cells were pretreated with 10 µM CB-1158 or buffer in the FLIPR dye solution. At the 10-minute point, 1 mM L-arginine (Arg) was added into the apical buffer, and, at 25 minutes, cAMP stimulation (Stim) occurred due to 10 µM FSK and 1 µM VX-770 addition. At 45 minutes, CFTR-specific inhibitor, CFTRinh-172 (Inh172), was added to confirm CFTR-specific function. (E) Representative trace shows Ussing chamber measurements of CFTR function in nasal cell culture from CF patients bearing F508del/F508del pretreated with VX-809 for 48 hours in absence (left) or presence of CB-1158 plus arginine (1 mM) for 1 hour (right). CFTR function was determined after inhibition of the epithelial sodium channel (ENaC) with 30 µM amiloride and cAMP activation with 10 µM FSK. The subsequent addition included 10 µM CFTRinh-172 to determine CFTR-specific activity. (F) Bar graph showing mean (±S.D.) FSK and VX-770–activated short-circuit transepithelial current (ISC) for nasal cultures from three patients bearing F508del/F508del mutation, after pretreatment of 48 hours with VX-809 (3 µM) Embedded Image CB-1158 (1 µM) (meanEmbedded Image S.D.). Unpaired t test was performed (**P = 0.0059, N = 3 biologic replicates, n = 1 technical replicate). For VX-809 or VX-809 plus CB1158 pretreatment, the confidence limits were 2.4–4.4 and 4.6–8.9 µA/cm2, respectively, using a confidential level of 95%.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Inhibition of arginase activity enhances rescue of CBF at the surface of primary respiratory epithelial tissues by VX-809 plus VX-770. Top panel: Bar graph represents CBF (Hertz) on F508del-CFTR primary bronchial cells with 48-hour chronic treatment of either DMSO or 3 µM VX-809 (meanEmbedded Image S.D.). Cells were pretreated with 1 mM L-arginine, 10 µM CB-1158, 10 µM ABH, or buffer in the HBSS solution following 1 hour of equilibration and 30 minutes of either 10 µM FSK (first bar) or 10 µM FSK with 1 µM VX-770 (remaining bars) apical addition to the HBSS. WT baseline is based on the mean FSK-stimulated values of eight individual WT-CFTR primary bronchial cells. One-way ANOVA with Tukey’s multiple comparison test was performed when comparing the first bar (VX-809 + VX-770) with the rest of the conditions (*P < 0.05; ****P < 0.0001, N > 3 biologic replicates, n = 2 technical replicates). Bottom panel: Bar graph represents FSK-stimulated CBF (Hertz) of the fully differentiated (day 30 postseeding) F508del-CFTR primary nasal cells with 48-hour chronic treatment of either DMSO or 3 µM VX-809 (meanEmbedded Image S.D.). Cells were pretreated with 1 mM L-arginine, 10 µM CB-1158, 10 µM ABH, or buffer in the HBSS solution following 1 hour of equilibration and 30 minutes of either 10 µM FSK (first bar) or 10 µM FSK with 1 µM VX-770 (remaining bars) apical addition to the HBSS. One-way ANOVA with Tukey’s multiple comparison test was performed (ns = not statistically significant, ***P = 0.001; ****P < 0.0001, N = 3 biologic replicates, n = 2 technical replicates).

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Velocity and pattern of bead movement are defective in F508del respiratory cultures. (A) Left: Representative MCCV of a WT bronchial epithelial insert. Each color represents an individual bead movement over the course of 10 seconds following 1-hour equilibration of WT-CFTR bronchial epithelial inserts in HBSS solution containing 0.02% polystyrene microspheres. MCCV appears as a mostly homogenous circular motion. Right: Representative MCCV of a F508del-CFTR bronchial epithelial insert shows less movement of each individual bead compared with the WT bronchial epithelial insert. (B) Bar graph represents the raw MCCV (micrometers per second) of either WT-CFTR or F508del-CFTR primary bronchial cells with 48-hour chronic treatment of DMSO (mean ± S.D.). Cells were pretreated with buffer in the HBSS solution containing 1 µm green or red polystyrene microspheres (0.02%) following 1 hour of equilibration. Unpaired t test was performed (****P < 0.0001, N > 8 biologic replicates, n = 1 technical replicate).

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Inhibition of arginase activity enhances rescue of MCCV on the surface of primary respiratory epithelial tissues by VX-809 plus VX-770. (A) Bar graph represents MCCV (micrometers per second) of F508del-CFTR primary bronchial cells with 48-hour chronic treatment of either DMSO or 3 µM VX-809 (meanEmbedded Image S.D.). Cells were pretreated with 1 mM L-arginine, 10 µM CB-1158, 10 µM ABH, or buffer in the HBSS solution containing 1 µm green or red polystyrene microspheres (0.02%) following 1 hour of equilibration and 30 minutes of either 10 µM FSK or 10 µM FSK with 1 µM VX-770 apical addition to the HBSS. WT baseline is based on the mean FSK-stimulated values of eight individual WT-CFTR primary bronchial cells. The MCCV values were normalized to each biologic replicate’s respective VX-809 plus VX-770 treatment. One-way ANOVA with Tukey’s multiple comparison test was performed (**P < 0.007; ****P < 0.0001, N > 4 biologic replicates, n = 3 technical replicates). (B) Connected line plot represents the FSK-stimulated MCCV (micrometers per second) of the fully differentiated (day 30 postseeding) F508del-CFTR primary nasal cells treated with 3 µM VX-809 following equilibration in HBSS solution containing 1 µm polystyrene microspheres (0.02%) for 1 hour. Each dot represents an individual biologic replicate (n = 2 to 3 technical replicates). Paired t test was performed (*P < 0.05, N = 3 biologic replicates, n = 2 technical replicates). (C) Bar graph represents MCCV of the fully differentiated (day 30 postseeding) F508del-CFTR primary nasal cells with 48-hour chronic treatment of either DMSO or 3 µM VX-809 (meanEmbedded Image S.D.). Cells were pretreated with 1 mM L-arginine, 10 µM CB-1158, 10 µM ABH, or buffer in the HBSS solution containing 1 µM green or red polystyrene microspheres following 1 hour of equilibration and 30 minutes of either 10 µM FSK or 10 µM FSK with 1 µM VX-770 apical addition to the HBSS. The MCCV values were normalized to each biologic replicate’s respective VX-809 plus VX-770 treatment. One-way ANOVA with Tukey’s multiple comparison test was performed (ns = not statistically significant, *P < 0.05, N = 3 biologic replicates, n = 2 to 3 technical replicates).

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Restoration of normal channel function translates to complete rescue of CBF but only partial rescue of MCCV in VX-809 plus VX-770–treated bronchial epithelia from patients homozygous for F508del. CFTR channel activity, CBF, and MCCV outcome measurements of three conditions treated with 10 µM FSK: 48-hour DMSO (red), 48-hour VX-809 plus VX-770 (blue), and 48-hour VX-809 plus VX-770 with CB-1158 and arginine (green), which were normalized to experimental WT controls and plotted against channel activity. Left: CFTR channel activity was plotted against CBF, and the equation of the line graph was generated by calculating linear regression using Spearman’s correlation test (****P < 0.0001, r = 0.867). Right: CFTR channel activity was plotted against MCCV, and the equation of the line graph was generated by calculating linear regression using Spearman’s correlation test (r = 0.8854).

  • Fig. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    Combinational therapy with VX-809 plus VX-770 and L-arginine–NO pathway agonists can ameliorate the CFTR channel activity, CBF, and mucociliary clearance defects observed in F508del-CFTR respiratory tissues. Increased protein kinase G (PKG) phosphorylation activates CFTR channel activity and the ATPase motor of cilia to increase ciliary beating. In CF patients, there is increased arginase expression, which results in a buildup of proline (buildup of fibrotic mass) and polyamine (inhibitor of NO synthase activity). This, in turn, decreases NO synthase expression and activity, decreases NO production, and consequently decreases CFTR channel activity and cilia motility. By using L-arginine–NO pathway agonists in VX-809 plus VX-770–rescued F508del-CFTR tissue, PKG and protein kinase A (PKA) agonists in conjunction activate corrected CFTR at the apical surface as well as the ATPase motor of cilia, resulting in a higher pH and less viscous environment for metachronal ciliary beating and thus mucociliary clearance to occur.

Additional Files

  • Figures
  • Data Supplement

    • Supplemental Data -

      Supplementary Table 1 - Age and gender listed for each patient, homozygous for F508del and associated with CF code number.

      Supplementary Figure 1 - Structure of arginase inhibitors: CB1158 and ABH.

      Supplementary Figure 2 - Addition of arginase inhibitor (CB1158) in the absence of extracellular arginine fails to enhance channel function rescued by ORKAMBI.

      Supplementary Figure 3 - NO modulators influence CBF and MCCV in WT primary human bronchial cells.

      Supplementary Figure  4 -The arginase inhibitor CB-158 does not affect CFTR protein levels in F508del-CFTR nasal epithelial cells.

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 96 (4)
Molecular Pharmacology
Vol. 96, Issue 4
1 Oct 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Chann…
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Nitric Oxide Boosts Rescue of F508del-CFTR by ORKAMBI

Yu-Sheng Wu, Janet Jiang, Saumel Ahmadi, Alexandria Lew, Onofrio Laselva, Sunny Xia, Claire Bartlett, Wan Ip, Leigh Wellhauser, Hong Ouyang, Tanja Gonska, Theo J. Moraes and Christine E. Bear
Molecular Pharmacology October 1, 2019, 96 (4) 515-525; DOI: https://doi.org/10.1124/mol.119.117143

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Nitric Oxide Boosts Rescue of F508del-CFTR by ORKAMBI

Yu-Sheng Wu, Janet Jiang, Saumel Ahmadi, Alexandria Lew, Onofrio Laselva, Sunny Xia, Claire Bartlett, Wan Ip, Leigh Wellhauser, Hong Ouyang, Tanja Gonska, Theo J. Moraes and Christine E. Bear
Molecular Pharmacology October 1, 2019, 96 (4) 515-525; DOI: https://doi.org/10.1124/mol.119.117143
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • GABAAR Molecular Identity in Oligodendrocytes
  • Editing TOP2α Intron-19 5′ SS Circumvents Drug Resistance
  • SerpinA3N and drug induced liver injury
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics